新股暗盤丨歸創通橋-B(2190.HK)暗盤段一度漲超45%
格隆匯7月2日丨歸創通橋-B(2190.HK)暗盤段最高報62.2港元,較發行價42.70港元漲45.7%。該股IPO定價為42.70港元/股。香港公開發售部分獲超額認購逾1,190倍,國際發售部分也獲得非常高的超額認購。在不考慮香港公開發售部分回撥的情況下,國際發售部分亦錄得超過22.5倍認購;在考慮香港公開發售部分回撥的情況下,如果扣除基石投資人鎖定的部分,國際發售部分超額認購超過94倍(包括綠鞋部分)。公司此次IPO獲得了多達12家基石投資機構的青睞,包括高瓴資本、富達基金、清池資本、雪湖資本等,共認購1.45億美元股份。近日,公司研發的ZYLOX Boa抓捕器獲得NMPA上市許可,比預期2021Q3提前1-2個月。ZYLOX Boa抓捕器與此前已上市的ZYLOX腔靜脈濾器抓捕器一同構成了歸創通橋目前在治療靜脈血栓栓塞症(VTE)方面的解決方案,也進一步豐富了歸創通橋在治療靜脈系統疾病的產品線佈局。此外,公司在CE市場推出CYLONETM吸栓導管。繼去年推出血栓回收裝置後,公司為急性缺血性中風患者和他們的照顧者帶來了新的選擇。公司的研發節奏非常迅猛,今年上半年已經成功獲取4個批件。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.